Agents Used in Antiretroviral Therapy

  • Authors: Philip Grant, MD (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 7/19/21 (What's New)

Summary

  • In 2021, injectable cabotegravir plus injectable rilpivirine was approved for the treatment of HIV infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine[FDA CAB RPV]
  • The ATLAS study showed noninferiority of switching to monthly intramuscular injections of [drug: cabotegravir] plus rilpivirine (following a short lead-in with oral formulations of both drugs) vs continued baseline ART in patients on stable ART[Swindells 2020]
  • The FLAIR study showed noninferiority of monthly intramuscular injections of [drug: cabotegravir] plus rilpivirine (following a short lead-in with oral formulations of both drugs) vs abacavir/dolutegravir/lamivudine in patients with stable virologic suppression following 20 weeks of initial ART with abacavir/dolutegravir/lamivudine[Orkin 2020]

Action required

Keywords: Initial Antiretroviral Therapy, Special Populations, Treatment Complications

©2020 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.